Senior Vice President of $DHI sells 260 shares in insider sale

A recent Securities and Exchange Commission filing revealed that Aron M. Odom, the Senior Vice President (SVP) of $DHI, executed a sale of 260 shares of the company on February 13, 2026, netting approximately $43,563. This transaction represented a divestment of around 3.9% of Odom’s holdings in this class of stock, leaving him with 6,457 remaining shares of $DHI.

In the past six months, insiders at $DHI have engaged in open market stock trades four times, with all four transactions involving sales rather than purchases. Among these, David V Auld, the Executive Chairman, offloaded 30,000 shares for an estimated $5,466,411. Aron M. Odom, in addition to his recent sale, carried out another divestment of 1,636 shares, totaling approximately $295,371. Michael R. Buchanan also participated in the selling spree by shedding 1,000 shares for $180,740.

Moving to hedge fund activity, a notable trend emerged with 498 institutional investors opting to increase their ownership of $DHI shares, while 690 reduced their positions in the last quarter. Major transactions included UBS AM, an entity of UBS Asset Management Americas LLC, disposing of 7,158,668 shares representing a 74.7% decrease valued at $1,031,062,952 during Q4 2025. Conversely, CAPITAL WORLD INVESTORS surged ahead by adding 6,695,592 shares, translating to a 22.1% increase and valued at $964,366,115 in their Q4 2025 portfolio. JPMORGAN CHASE & CO opted to slash 3,639,413 shares, marking a 34.6% reduction valued at $524,184,654, in the same period.

Shifting focus to congressional stock trading, members of Congress dabbled in $DHI shares, conducting five transactions, with two being purchases and three sales in the last half-year. Representative Gilbert Ray Cisneros, Jr. engaged in trading twice, making one purchase and one sale, each valued at up to $15,000. Representative Lisa C. McClain was more active, executing three trades, comprising one purchase and two sales, with the sales totaling up to $30,000.

Further analysis reveals that Wall Street analysts provided insight into $DHI’s performance, with two firms issuing buy ratings and one issuing a sell rating. Notable recommendations include a “Buy” rating from UBS on January 6, 2026. On the price target front, nine analysts offered projections for $DHI in the past six months, with the median target resting at $158.0. Analysts such as Christopher Graja from Argus Research set a target price of $185.0 on January 23, 2026, marking one of the high-end projections, while others, like Matthew Bouley from Barclays, aimed for $129.0.

This article serves to provide informative content and should not be misconstrued as financial advice. For a comprehensive overview of insider trading, hedge fund activity, congressional stock trading, analyst ratings, and price targets for $DHI, viewers can refer to Quiver Quantitative’s specialized dashboards dedicated to each respective category.